Results 201 to 210 of about 73,125 (286)

S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditäten

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 2, Page 270-284, February 2026.
Zusammenfassung Der vorliegende Teil 2 der aktualisierten S3‐Leitlinie zur Therapie der Psoriasis vulgaris bietet Empfehlungen zur Therapieauswahl in besonderen klinischen Situationen sowie bei Vorliegen von Komorbidität. Ein Schwerpunkt des Updates liegt im Kapitel Screening auf Tuberkulose sowie in der Therapieauswahl und im Management bei latenter ...
Alexander Nast, Andreas Altenburg, Matthias Augustin, Frank Bachmann, Wolf‐Henning Boehncke, Markus Cornberg, Hilte Geerdes‐Fenge, Brit Häcker, Peter Härle, Joachim Klaus, Michaela Köhm, Arno Köllner, Ulrich Mrowietz, Hans‐Michael Ockenfels, Antonia Pennitz, Sandra Philipp, Thomas Richter, Thomas Rosenbach, Tom Schaberg, Martin Schlaeger, Gerhard Schmid‐Ott, Michael Sebastian, Karisa Thölken, Ralph von Kiedrowski, Uwe Willuhn, Christoph Zeyen   +25 more
wiley   +1 more source

Development of an NGS-Based Estimation of Integrated HBV DNA in Liver Biopsies and Detection in Liquid Biopsies. [PDF]

J Med Virol
Liu HN, Lin SY, Ramirez R, Chen SE, Heimer ZR, Kubas R, Shieh FS, Kim ES, Liu Y, Lau DTY, Chang TT, Guo H, Wang Z, Su YH.   +13 more
europepmc   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

European Journal of Haematology, Volume 116, Issue 2, Page 174-184, February 2026.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi, Annamaria Vincenzi, Claudia Giordano, Novella Pugliese, Alessia Scarpa, Assunta Lombardi, Elena Vigliar, Giancarlo Troncone, Rosaria Cappiello, Massimo Mascolo, Giovanni Esposito, Maria Prastaro, Ciro Santoro, Roberta Esposito, Carlo Gabriele Tocchetti, Ciro Mainolfi, Rosa Fonti, Silvana Del Vecchio, Fabio Trastulli, Mario Annunziata, Rossella Iula, Catello Califano, Marianna Carchia, Marcello Persico, Alessia Salemme, Emanuele Nicolai, Andrea Soricelli, Marco Salvatore, Fabrizio Pane   +28 more
wiley   +1 more source

Tissue-resident memory CD8+T cells might enhance HBV DNA clearance in CHB patients with MASLD complication and normal ALT via the CCL-CCR pathways. [PDF]

Front Cell Infect Microbiol
Cai C, Shang WX, Zheng SJ, Chen C, Xu K, Chen L, Wang YJ, Wang YQ, Chen RC, Cai YJ, Zhang HF, Huang C, Lin J, Zhou BG, Lin XL, Zhang L, Lu MQ.   +16 more
europepmc   +1 more source

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, Volume 56, Issue 2, Page 246-252, February 2026.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source

Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors. [PDF]

Ther Adv Med Oncol
Qin Q, Zheng Y, Wang Y, Zhou F, Li D, Jin L, Zhu M, Guo Y, Fan R, Hou J, Zhang X, Liu H.   +11 more
europepmc   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

HIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill   +6 more
wiley   +1 more source

The Effect of MAFLD on Hepatocarcinogenesis in HBeAg-negative Patients with Undetectable HBV-DNA under NA Therapy: A Multicenter Study. [PDF]

Intern Med
Amano K, Sano T, Ide T, Nakano D, Tsutsumi T, Arinaga-Hino T, Kawaguchi M, Hirai S, Miyajima I, Torimura T, Kawaguchi T.   +10 more
europepmc   +1 more source

KLF1 Exerts Pro‐Tumour Role in Liver Cancer via Inhibiting ACSL4/LPCAT3‐Regulated Ferroptosis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Kruppel‐like factors (KLFs) constitute a crucial family of transcription factors that are engaged in a variety of biological processes, such as erythropoiesis as well as liver development. A growing body of research underscores the increasing importance of the KLF family in the context of hepatocellular carcinoma (HCC). Despite this, the exact
Zhihui Chen, Changyan Zhang, Jialin Yang, Yong Peng   +3 more
wiley   +1 more source

Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment. [PDF]

J Clin Invest
Taddese M, Grudda T, Belluccini G, Anderson M, Cloherty G, Hwang HS, Mani M, Lo CM, Esrig N, Sulkowski MS, Sterling RK, Zhang Y, Ribeiro RM, Thomas DL, Thio CL, Balagopal A.   +15 more
europepmc   +1 more source